646
Views
32
CrossRef citations to date
0
Altmetric
Research Article

Unique/Major Human Metabolites: Why, How, and When to Test for Safety in Animals

Pages 447-463 | Published online: 09 Oct 2008

REFERENCES

  • Amacher D. E. Reactive intermediates and the pathogenesis of adverse drug reactions: The toxicology perspective. Curr. Drug Metab. 2006; 7: 219–229
  • Baillie T. A., Cayen M. N., Fouda H., Gerson R. J., Green J. D., Grossman S. J., Klunk L. J., LeBlanc B., Perkins D. G., Shipley L. A. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 2002; 182: 188–196
  • Baillie T. A., Cayen M. N., Fouda H., Gerson R. J., Green J. D., Grossman S. J., Klunk L. J., LeBlanc B., Perkins D. G., Shipley L. A. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 2003; 190: 93–94
  • Chiu S. H. L., Huskey S. E. W. Species differences in N-glucuronidation. Drug Metab. Dispos. 1998; 26: 838–847
  • Davis-Bruno K. L., Atrakchi A. A regulatory perspective on issues and approaches in characterizing human metabolites. Chem Res. Toxicol. 2006; 19: 1561–1563
  • Doss G. A., Baillie T. A. Addressing metabolic activation as an integral component of drug design. Drug Metab. Rev. 2006; 38: 641–649
  • Evans D. C., Watt A. P., Nicoll-Griffith D. A., Baillie T. A. Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 2004; 17: 3–16
  • Food and Drug Administration. Guidance for Industry: Carcinogenicity Study Protocol Submissions. FDA, Rockville, MD. 2002
  • Food and Drug Administration. Guidance for Industry (Draft): Safety Testing of Drug Metabolites. FDA, Rockville, MD. 2005
  • Food and Drug Administration. Guidance for Industry: Safety Testing of Drug Metabolites. FDA, Rockville, MD. 2008
  • Guengerich F. P. Safety assessment of stable drug metabolites. Chem Res. Toxicol. 2006; 19: 1559–1560
  • Hastings K. L., El-Hage J., Jacobs A., Leighton J., Morse D., Osterberg R. E. Letter to the Editor. Toxicol. Appl. Pharmacol. 2003; 190: 91–92
  • Hawes E. M. N+-Glucuronidation, A common pathway in human metabolism of drugs with a tertiary amine group. Drug Metab Dispos. 1998; 26: 830–837
  • Humphreys W. G., Unger S. E. Safety assessment of drug metabolites: characterization of chemically stable metabolites. Chem Res. Toxicol. 2006; 19: 1564–1569
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline S1C: Dose Selection for Carcinogenicity Studies of Pharmaceuticals. ICH Steering Committee 1994
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline S1C(R1): Dose Selection for Carcinogenicity Studies of Pharmaceuticals & Limit Dose. ICH Steering Committee. 2005a
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline M3(R1): Maintenance of the ICH Guideline on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. ICH Steering Committee. 2005b
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline S1C(R2): Revision of ICH S1C(R1): Dose Selection for Carcinogenicity Studies of Pharmaceuticals & Limit Dose. ICH Steering Committee. 2006a
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline M3(R2): Revision of ICH M3(R1): Maintenance of the ICH Guideline on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. ICH Steering Committee. 2006b
  • Prueksaritanont T., Lin J. H., Baillie T. A. Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 2006; 217: 143–152
  • Smith D. A., Obach R. S. Seeing through the MIST: Abundance versus percentage. Commentary on Metabolites in Safety Testing. Drug Metab. Dispos. Fast Forward. 2005, doi:10.1124/dmd.105.005041.
  • Smith D. A., Obach R. S. Metabolites and safety: What are the concerns, and how should we address them?. Chem Res. Toxicol. 2006; 19: 1570–1579
  • World Health Organization (WHO). Toxicological Evaluation of Certain Food Additives and Contaminants. The 44th Meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA). WHO Food Additives Series 35 1996

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.